# 蘇州瑞博生命科學與Ribocure Pharmaceuticals宣布向歐洲藥品管理局（EMA）提交針對冠狀動脈疾病（CAD）治療的siRNA療法RBD1119的第二期臨床試驗申請（CTA）

*biotech · news · 2026-05-28 · The Manila Times*

## Key points

- 蘇州瑞博生命科學已向EMA提交RBD1119的第二期臨床試驗申請。
- RBD1119是一種基於siRNA的療法，針對冠狀動脈疾病，與傳統抗血栓藥物不同。
- 瑞博同時開發多個針對心房顫動和靜脈血栓栓塞的siRNA候選藥物。
- 目前的冠狀動脈疾病治療仍存在大量殘餘風險，凸顯對更安全抗血栓方法的未滿足需求。

SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease (CAD). Lately, Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established a world-leading anticoagulation/antithrombotic pipeline. This new submission for CAD represents an important milestone in Ribo's ambitious program to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases. Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk. "We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects our commitment to unlocking the full potential of RNA-based therapies to provide anticoagulant options with improved benefit-risk profile for patients not being adequately treated today." says Dr. Anders Gabrielsen, Chief Medical Officer of Ribo. Get the latest news delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

**Companies:** Suzhou Ribo Life Science, Ribocure Pharmaceuticals
**Countries:** 中國, 瑞典

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/28/tmt-newswire/pr-newswire/ribo-announces-phase-2-clinical-trial-submission-to-ema-further-advancing-sirna-therapeutics-in-thromboembolic-disease/2353268)

---

Canonical: https://newsio.io/zh-TW/n/2f7a77a1-fa30-4a09-b9be-9da45276cd5a/ribocure-pharmaceuticalsemacadsirnarbd1119cta
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works